School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Frederic Rahbari Oskoui MD

  • Department of Medicine
    Professor
  • (404) 727-2590
  • frahbar@emory.edu
Head shot of Frederic Rahbari Oskoui

Overview

Frederic Farid Rahbari-Oskoui, MD, MS is a practicing nephrologist and the director of Polycystic Kidney Disease Center of Excellence at Emory University.

Dr. Rahbari attended medical school at Universit de Bordeaux in France and obtained his MD (magna cum laude) in 1997 after completing a residency program in general medicine and partial nephrology training at the same institution. He worked as an attending physician in Normandy, France for two years before moving to the United States. Dr. Rhabari spent two years in clinical and translational research on oxidative stress, both at Universit de Bordeaux and at New York Medical College. He subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons from 2000-2003 and completed his academic track fellowship in nephrology at Emory University from 2003-2006, including an additional year in cystic and inherited diseases of the kidneys.

He joined the faculty at Emory University School of Medicines Division of Renal Medicine in July of 2006 at the rank of instructor. He was named an assistant professor of medicine in 2007 and an associate professor of medicine in 2014. During this time, he also obtained a master of science in clinical research (MSCR) degree from Emory University.

Dr. Rahbari is a diplomat of the American Board of Internal Medicine and is board-certified in nephrology.

He specializes in cystic diseases of the kidneys, inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in renal diseases, and he is involved in caring for patients with kidney diseases as well as conducting research in those fields.

He has co-authored more than 50 original manuscripts, review articles, and textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease.

He is a Fellow of the American Society of Nephrology, a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation, a member of the Emory University Promotions and Tenure Committee, and a member of the HALT-PKD Trial Steering Committee and the SPRINT Trial Publication and Presentations Committee.

He has been (and/or continues to be) an investigator in several landmark trials and observational cohorts:

1- HALT-PKD trial: Multi-center, randomized double-blind placebo controlled trial of multi-level blockage of the RAAS by ACE-I +/- ARBs in ADPKD (2004-2014)

2- TEMPO and REPRISE trials: Safety and Efficacy of the Vasopressin receptor antagonist Tolvaptan in ADPKD (2005-present)

3- The Systolic Blood pressure trial (SPRINT trial)

4- Consortium for Radiologic Imaging of Polycystic Kidney disease: CRISP

5- MUSE trial

6- The Melatonin in night-time blood pressure in African-Americans (MAP) trials

7- Pharmacogenomics of Essential Hypertension (PEAR trial)

8- PKD cohort study: Observational cohort of ADPKD patients followed for seven years

Academic Appointment

  • Professor of Medicine, Medicine-Renal, Emory Univeristy SOM
  • Master Clinician, Department of Medicine, Emory University School of Medicine
  • Associate Professor of Medicine, Medicine - Renal Medicine, Emory University School of Medicine
  • Instructor of Medicine, Department of Medicine-Renal Division, Emory University School of Medicine

Education

Degrees

  • The Third Cycle of French Medical Studies: (Residency in General Medicine and Doctoral Thesis) from University of Bordeaux-II
  • The Second Cycle of French Medical Studies, (Clinical Sciences) from Paul Broca School of Medical Sciences at the University Victor Segalen
  • The First Cycle of French Medical Studies, (Basic Sciences) from University of Bordeaux II
  • Master of Science in Clinical Research from T. Laney Graduate School Emory University
  • MD from University of Bordeaux-II France

Research

Focus

  • 1) Polycystic kidney disease: Clinical trials to halt progression of disease (HALT-PKD and four TEMPO trials), and observational cohorts on natural progression of disease (CRISP, Overture cohorts) 2) Ambulatory blood pressure monitoring (in ADPKD and essential hypertension). 3) Role of Melatonin on nocturnal hypertension. 4) Pharmacogenomics of response to antihypertensive therapy.

Publications

  • Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Clin J Am Soc Nephrol Volume: 20 Page(s): 520 - 528
    04/01/2025 Authors: Nowak KL; Copeland TP; Ku E; Sarnak MJ; Gitomer B; Abebe KZ; Chapman A; Perrone R; Rahbari-Oskoui FF; Steinman T
  • Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials.
    Am J Kidney Dis Volume: 85 Page(s): 127 - 130
    01/01/2025 Authors: Ku E; Copeland TP; McCulloch CE; Abebe KZ; Chonchol M; Perrone RD; Rahbari-Oskoui FF; Yu ASL; Steinman T; Chapman A
  • Polycystic Kidney Disease Diet: What is Known and What is Safe.
    Clin J Am Soc Nephrol Volume: 19 Page(s): 664 - 682
    05/01/2024 Authors: Chebib FT; Nowak KL; Chonchol MB; Bing K; Ghanem A; Rahbari-Oskoui FF; Dahl NK; Mrug M
  • Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT.
    Clin J Am Soc Nephrol Volume: 19 Page(s): 213 - 223
    02/01/2024 Authors: Drawz PE; Lenoir KM; Rai NK; Rastogi A; Chu CD; Rahbari-Oskoui FF; Whelton PK; Thomas G; McWilliams A; Agarwal AK
  • Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
    Lancet Diabetes Endocrinol Volume: 12 Page(s): 51 - 60
    01/01/2024 Authors: EMPA-KIDNEY Collaborative Group
  • Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    Lancet Diabetes Endocrinol Volume: 12 Page(s): 39 - 50
    01/01/2024 Authors: EMPA-KIDNEY Collaborative Group
  • Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease.
    Adv Kidney Dis Health Volume: 30 Page(s): 417 - 428
    09/01/2023 Authors: Rahbari-Oskoui FF
  • Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.
    Kidney Int Volume: 104 Page(s): 334 - 342
    08/01/2023 Authors: Gregory AV; Chebib FT; Poudyal B; Holmes HL; Yu ASL; Landsittel DP; Bae KT; Chapman AB; Frederic R-O; Mrug M
  • TESEVATINIB (KD019) VS PLACEBO FOR ADPKD: RESULTS OF A PH2B TRIAL
    Volume: 81 Page(s): S102 - S102
    04/01/2023 Authors: Rastogi A; Fada G; Rahbari-Oskoui F; Park M; Dahl N; Perrone R; Yang Z; Bhattacharya S; Herrera K; Eizenhamer D
  • Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study.
    Kidney360 Volume: 3 Page(s): 1253 - 1262
    07/28/2022 Authors: Drawz PE; Rai NK; Lenoir KM; Suarez M; Powell JR; Raj DS; Beddhu S; Agarwal AK; Soman S; Whelton PK
  • Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
    Am J Kidney Dis Volume: 79 Page(s): 677 - 687.e1
    05/01/2022 Authors: Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J
  • Association of Net Worth and Ambulatory Blood Pressure in Early Middle-aged African American Women.
    JAMA Netw Open Volume: 5 Page(s): e220331
    02/01/2022 Authors: Spikes T; Murden R; McKinnon II; Bromfield S; Van Dyke ME; Moore RH; Rahbari-Oskoui FF; Quyummi A; Vaccarino V; Lewis TT
  • Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
    N Engl J Med Volume: 384 Page(s): 1921 - 1930
    05/20/2021 Authors: SPRINT Research Group; Lewis CE; Fine LJ; Beddhu S; Cheung AK; Cushman WC; Cutler JA; Evans GW; Johnson KC; Kitzman DW
  • Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial.
    JAMA Neurol Volume: 78 Page(s): 568 - 577
    05/01/2021 Authors: Nasrallah IM; Gaussoin SA; Pomponio R; Dolui S; Erus G; Wright CB; Launer LJ; Detre JA; Wolk DA; Davatzikos C
  • Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
    Kidney Int Rep Volume: 6 Page(s): 953 - 961
    04/01/2021 Authors: El Ters M; Lu P; Mahnken JD; Stubbs JR; Zhang S; Wallace DP; Grantham JJ; Chapman AB; Torres VE; Harris PC
  • Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
    Am J Kidney Dis Volume: 77 Page(s): 255 - 263
    02/01/2021 Authors: Cho Y; Tong A; Craig JC; Mustafa RA; Chapman A; Perrone RD; Ahn C; Fowler K; Torres V; Gansevoort RT
  • Epidemiology of COVID-19 Infection in Hospitalized End-Stage Kidney Disease Patients in a Predominantly African-American Population.
    Am J Nephrol Volume: 52 Page(s): 190 - 198
    01/01/2021 Authors: Navarrete JE; Tong DC; Cobb J; Rahbari-Oskoui FF; Hosein D; Caberto SC; Lea JP; Franch HA
  • Managing COVID-19-positive Solid Organ Transplant Recipients in the Community: What a Community Healthcare Provider Needs to Know.
    Transplant Direct Volume: 6 Page(s): e633
    12/01/2020 Authors: Basu A; Patzer R; Hosein D; Wang Z; Sharma N; Franch H; Rahbari Oskoui F; Gupta D; Subramanian R; Sridharan L
  • Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice.
    JAMA Intern Med Volume: 180 Page(s): 1655 - 1663
    12/01/2020 Authors: Drawz PE; Agarwal A; Dwyer JP; Horwitz E; Lash J; Lenoir K; McWilliams A; Oparil S; Rahbari-Oskoui F; Rahman M
  • The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
    JCI Insight Volume: 5
    08/06/2020 Authors: Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF
  • Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
    J Am Soc Nephrol Volume: 31 Page(s): 1640 - 1651
    07/01/2020 Authors: Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE
  • Network Stressors, Personal Stressors, And Sustained Hypertension In African American Women
    Volume: 141
    03/03/2020 Authors: Spikes T; Scully L; Bromfield S; Van Dyke M; Moore R; McKinnon I; Booker B; Rahbari-Oskoui F; Quyyumi A; Vaccarino V
  • Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.
    Kidney Int Volume: 97 Page(s): 370 - 382
    02/01/2020 Authors: Hopp K; Cornec-Le Gall E; Senum SR; Te Paske IBAW; Raj S; Lavu S; Baheti S; Edwards ME; Madsen CD; Heyer CM
  • Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
    Kidney Int Volume: 95 Page(s): 1253 - 1261
    05/01/2019 Authors: Yu ASL; Shen C; Landsittel DP; Grantham JJ; Cook LT; Torres VE; Chapman AB; Bae KT; Mrug M; Harris PC
  • Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.
    Complement Ther Med Volume: 43 Page(s): 157 - 164
    04/01/2019 Authors: Rahbari-Oskoui FF; Abramson JL; Bruckman AM; Chapman AB; Cotsonis GA; Johnson SA; Bliwise DL
  • Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
    BMC Nephrol Volume: 19 Page(s): 378
    12/27/2018 Authors: McKenzie KA; El Ters M; Torres VE; Harris PC; Chapman AB; Mrug M; Rahbari-Oskoui FF; Bae KT; Landsittel DP; Bennett WM
  • Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.
    Kidney Int Rep Volume: 3 Page(s): 619 - 624
    05/01/2018 Authors: Dad T; Abebe KZ; Bae KT; Comer D; Torres VE; Czarnecki PG; Schrier RW; Steinman TI; Moore CG; Chapman AB
  • Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
    Am J Kidney Dis Volume: 71 Page(s): 666 - 676
    05/01/2018 Authors: Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF
  • Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Kidney Int Volume: 93 Page(s): 691 - 699
    03/01/2018 Authors: Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF
  • Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Am J Kidney Dis Volume: 71 Page(s): 352 - 361
    03/01/2018 Authors: Rocco MV; Sink KM; Lovato LC; Wolfgram DF; Wiegmann TB; Wall BM; Umanath K; Rahbari-Oskoui F; Porter AC; Pisoni R
  • ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.
    Am J Kidney Dis Volume: 71 Page(s): 294 - 296
    02/01/2018 Authors: Braun WE; Abebe KZ; Brosnahan G; Patterson CG; Chapman AB; Harris PC; Hogan MC; Perrone RD; Torres VE; Miskulin DC
  • Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
    J Am Soc Nephrol Volume: 29 Page(s): 571 - 578
    02/01/2018 Authors: Nowak KL; You Z; Gitomer B; Brosnahan G; Torres VE; Chapman AB; Perrone RD; Steinman TI; Abebe KZ; Rahbari-Oskoui FF
  • Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Curr Hypertens Rev Volume: 14 Page(s): 39 - 47
    01/01/2018 Authors: Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD
  • Hypoxia-Inducible Factor 1 (HIF-1), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease.
    Am J Nephrol Volume: 47 Page(s): 228 - 230
    01/01/2018 Authors: Rahbari-Oskoui FF; Chapman AB
  • Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    N Engl J Med Volume: 377 Page(s): 1930 - 1942
    11/16/2017 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS
  • Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.
    N Engl J Med Volume: 377 Page(s): 733 - 744
    08/24/2017 Authors: Berlowitz DR; Foy CG; Kazis LE; Bolin LP; Conroy MB; Fitzpatrick P; Gure TR; Kimmel PL; Kirchner K; Morisky DE
  • Diagnosis and Management of Acquired Cystic Kidney Disease and Renal Tumors in ESRD Patients.
    Semin Dial Volume: 30 Page(s): 373 - 379
    07/01/2017 Authors: Rahbari-Oskoui F; O'Neill WC
  • ALDOSTERONISM IN POLYCYSTIC KIDNEY DISEASE: HYPERTENSION BIDING IN PLAIN SIGHT
    Volume: 69 Page(s): A56 - A56
    04/01/2017 Authors: Kashyap C; Bailey JL; Rahbari-Oskoui F
  • Dietary salt restriction is beneficial to the management of autosomal dominant polycystickidney disease.
    Kidney Int Volume: 91 Page(s): 493 - 500
    02/01/2017 Authors: Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC
  • Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Curr Hypertens Rev Volume: 13 Page(s): 109 - 120
    01/01/2017 Authors: Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC
  • A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
    N Engl J Med Volume: 373 Page(s): 2103 - 2116
    11/26/2015 Authors: SPRINT Research Group; Wright JT; Williamson JD; Whelton PK; Snyder JK; Sink KM; Rocco MV; Reboussin DM; Rahman M; Oparil S
  • Closeout of the HALT-PKD trials.
    Contemp Clin Trials Volume: 44 Page(s): 48 - 55
    09/01/2015 Authors: Moore CG; Spillane S; Simon G; Maxwell B; Rahbari-Oskoui FF; Braun WE; Chapman AB; Schrier RW; Torres VE; Perrone RD
  • A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
    Kidney Int Volume: 88 Page(s): 146 - 151
    07/01/2015 Authors: Bhutani H; Smith V; Rahbari-Oskoui F; Mittal A; Grantham JJ; Torres VE; Mrug M; Bae KT; Wu Z; Ge Y
  • Liver involvement in early autosomal-dominant polycystic kidney disease.
    Clin Gastroenterol Hepatol Volume: 13 Page(s): 155 - 64.e6
    01/01/2015 Authors: Hogan MC; Abebe K; Torres VE; Chapman AB; Bae KT; Tao C; Sun H; Perrone RD; Steinman TI; Braun W
  • Angiotensin blockade in late autosomal dominant polycystic kidney disease.
    N Engl J Med Volume: 371 Page(s): 2267 - 2276
    12/11/2014 Authors: Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC
  • Blood pressure in early autosomal dominant polycystic kidney disease.
    N Engl J Med Volume: 371 Page(s): 2255 - 2266
    12/11/2014 Authors: Schrier RW; Abebe KZ; Perrone RD; Torres VE; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC
  • Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
    Nephrol Dial Transplant Volume: 29 Page(s): 2194 - 2201
    12/01/2014 Authors: Rahbari-Oskoui F; Williams O; Chapman A
  • CHARACTERISTICS OF ADPKD PATIENTS WITH RAPID PROGRESSION TO RENAL FAILURE: LESSONS FROM CRISP.
    Volume: 63 Page(s): A37 - A37
    05/01/2014 Authors: Chapman AB; Gibbs P; Rahbari-Oskoui F; Bae T; Bhutani HS; Grantham J; Harris P; Mrug M; Torres V; Yu A
  • Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1.
    Clin J Am Soc Nephrol Volume: 9 Page(s): 527 - 535
    03/01/2014 Authors: Bleyer AJ; Kmoch S; Antignac C; Robins V; Kidd K; Kelsoe JR; Hladik G; Klemmer P; Knohl SJ; Scheinman SJ
  • Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Am J Kidney Dis Volume: 63 Page(s): 214 - 226
    02/01/2014 Authors: Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC
  • Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease.
    Clin J Am Soc Nephrol Volume: 9 Page(s): 406 - 415
    02/01/2014 Authors: Rahbari-Oskoui F; Mittal A; Mittal P; Chapman A
  • Impact of MALDI-TOF will be highly dependent on the clinician.
    Clin Infect Dis Volume: 57 Page(s): 1501 - 1502
    11/01/2013 Authors: Braud G; Garcia M; Rahbari-Oskoui FF
  • Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature.
    Case Rep Nephrol Volume: 2013 Page(s): 651246
    01/01/2013 Authors: Rahbari-Oskoui F; Fielder O; Ghasemzadeh N; Hennigar R
  • Analysis of baseline parameters in the HALT polycystic kidney disease trials.
    Kidney Int Volume: 81 Page(s): 577 - 585
    03/01/2012 Authors: Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT
  • Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Clin J Am Soc Nephrol Volume: 6 Page(s): 2499 - 2507
    10/01/2011 Authors: Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB
  • Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.
    Clin J Am Soc Nephrol Volume: 6 Page(s): 2508 - 2515
    10/01/2011 Authors: Perrone RD; Abebe KZ; Schrier RW; Chapman AB; Torres VE; Bost J; Kaya D; Miskulin DC; Steinman TI; Braun W
  • Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.
    Blood Press Monit Volume: 16 Page(s): 47 - 54
    04/01/2011 Authors: Rahbari-Oskoui FF; Miskulin DC; Hogan MC; Fielder O; Torres VE; Bost JE; Chapman AB
  • Angiotensin II receptor blockers and risk of cancer: cause for concern?
    Am J Kidney Dis Volume: 57 Page(s): 7 - 10
    01/01/2011 Authors: Rahbari-Oskoui F
  • HYPERCALCEMIA ASSOCIATED WITH GLUTEAL SILICONE INJECTIONS: A CASE REPORT
    Volume: 55 Page(s): A103 - A103
    04/01/2010 Authors: Singapuri S; Patel D; Rahbari-Oskoui F
  • Hypertension in autosomal dominant polycystic kidney disease.
    Adv Chronic Kidney Dis Volume: 17 Page(s): 153 - 163
    03/01/2010 Authors: Chapman AB; Stepniakowski K; Rahbari-Oskoui F
  • The HALT polycystic kidney disease trials: design and implementation.
    Clin J Am Soc Nephrol Volume: 5 Page(s): 102 - 109
    01/01/2010 Authors: Chapman AB; Torres VE; Perrone RD; Steinman TI; Bae KT; Miller JP; Miskulin DC; Rahbari Oskoui F; Masoumi A; Hogan MC
  • Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
    Clin J Am Soc Nephrol Volume: 4 Page(s): 560 - 566
    03/01/2009 Authors: Rizk D; Jurkovitz C; Veledar E; Bagby S; Baumgarten DA; Rahbari-Oskoui F; Steinman T; Chapman AB
  • Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
    Am J Hypertens Volume: 21 Page(s): 61 - 66
    01/01/2008 Authors: Canzanello VJ; Baranco-Pryor E; Rahbari-Oskoui F; Schwartz GL; Boerwinkle E; Turner ST; Chapman AB
  • Heritability estimates (H2) of disease severity in autosomal dominant polycystic kidney disease: Genetic contributions to renal volume measures.
    JOURNAL OF INVESTIGATIVE MEDICINE Volume: 53 Page(s): S313 - S313
    01/01/2005 Authors: Rahbari-Oskoui F; Rizk D; Ladson J; Barkley RA; Paxton W; Arya K; Chapman A; Boerwinkle E
  • Increased oxidative stress in younger as well as in older humans.
    Clin Chim Acta Volume: 328 Page(s): 83 - 86
    02/01/2003 Authors: Phillips M; Cataneo RN; Greenberg J; Gunawardena R; Rahbari-Oskoui F
  • Volatile markers of breast cancer in the breath.
    Breast J Volume: 9 Page(s): 184 - 191
    01/01/2003 Authors: Phillips M; Cataneo RN; Ditkoff BA; Fisher P; Greenberg J; Gunawardena R; Kwon CS; Rahbari-Oskoui F; Wong C
  • Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress.
    J Lab Clin Med Volume: 136 Page(s): 243 - 249
    09/01/2000 Authors: Phillips M; Cataneo RN; Greenberg J; Gunawardena R; Naidu A; Rahbari-Oskoui F
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements